These awards have become one of the highlights in the European biotech calendar, with over 200 SMEs competing over the years. The submission deadline has been extended to October 21, 2018.
Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites worldwide primarily in the US; topline data readout expected in Q2 2026 with NDA submission to follow
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life- threatening diseases, announced today that the first participant has been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bio
Cytosurge appoints Dr. Magid Haddouchi as Chief Commercial Officer to drive global expansion. With over 15 years of experience, he joins as the company engages in key 2025 events, including AACR (USA), SPMConnect (USA), and ISSCR (Hong Kong). Dr. Haddouchi will focus on expanding the reach of FluidFM technology in single-cell research and precision genome editing, enhancing customer engagement, an